
Horizon Discovery and University of Washington Expand Gene-Targeting Licenses to Include Bioproduction & Stem Cell Applications
The new agreements give Horizon a world-wide exclusive right to commercialize inventions relating to the use of parvoviral vectors in human genome engineering.
Article
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
The enlarged company, to be called Silence Therapeutics, will have multiple RNAi discovery, development and delivery technologies, a broad internal and partnered product pipeline and a broad portfolio of intellectual property.
Article
Caltech, UCLA Launch Joint Center for Translational Medicine
The California Institute of Technology (Caltech) and the University of California, Los Angeles (UCLA) have announced the establishment of the Joint Center for Translational Medicine, which will advance experimental research into clinical applications, including the diagnosis and therapy of diseases such as cancer.
Article
School of Medicine Receives Grant to Coordinate a Consortium of National Stem Cell Experts
Michael L. Terrin, MD, CM, MPH, professor of epidemiology and preventive medicine, was chosen by the National Heart, Lung and Blood Institute (NHLBI) to coordinate the research of this consortium of national experts, which will be called the NHLBI Progenitor Cell Biology Consortium.
Article
Indiana Industry, University and Community Leaders Capitalize on Next Generation of State’s Life Sciences Growth
Capitalizing on the continued strong growth of Indiana’s life sciences industry and an active venture capital market, leaders from BioCrossroads, Eli Lilly and Company, Indiana State Teachers Retirement Fund, Indiana University, Purdue University, the University of Notre Dame, Richard M. Fairbanks Foundation, and Credit Suisse recently announced the establishment of the INext Fund, a $58 million venture capital fund of funds.
Article
Boston University School of Medicine’s Pulmonary Center Receives $1.4 Million Grant
Boston University School of Medicine’s Pulmonary Center has received a two-year $1.4 million grant from the National Heart, Lung, and Blood Institute to derive stem cells and lung progenitors from patients with lung disease.
Article
Amsterdam Molecular Therapeutics Successfully Raises EUR 5 Million via a Convertible Bond Issue with Shareholder Forbion
Amsterdam Molecular Therapeutics intends to use the net proceeds from the issue to further strengthen its focused pipeline development activities in the areas of Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and Parkinson’s Disease.
Article
UK Lays Out Regulatory Roadmap for Stem Cell Treatments
The UK Department of Health has drawn up a regulatory roadmap to guide stem cell researchers seeking to get treatments to clinics, following complaints that progress is being blocked by bureaucratic complexities.
Article
U.S. Patent Office Grants Geron’s Request for an Interference with U.S. Patent No. 7,510,876 to Novocell
Geron Corporation recently announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 owned by Novocell, Inc. The patent filings cover technology for the differentiation of human embryonic stem cells into the precursors of numerous endoderm cell types, including pancreatic islet cells.
Article
Isis and Alnylam Announce Notice of Allowance for New U.S. Patent Application Broadly Covering RNAi Therapeutics
Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced recently that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.
Article
StemCells, Inc. Strengthens Patent Position in Embryonic and Induced Pluripotent Stem Cell Technology Platforms
StemCells, Inc. announced that it has received a Notice of Allowance and a Notice of Issuance from the U.S. Patent and Trademark Office for two patents claiming technologies for the establishment and maintenance of cell pluripotency, including the reprogramming of cells to create pluripotent stem cells.
Article